VU-2-G7 is a type of IgG1 kappa murine mAb developed based on the synthesized 60-mer MUC1 triple TP peptide that contains the GalNAc O linked to threonine within the PDTR region, whereas VU-2-G7’s predominant epitope is present within MUC1 TP’s glycosylated PDTR motif, which shows high abundance in the cancer cell surface of OC/BRCA tissues. Here, MUC1 is linked to cancer.